Pfizer Expects To Pay $772M To End Hormone Drug Suits
The pharmaceutical giant has been hit with thousands of suits claiming it pedaled its hormone-replacement therapy drugs to menopausal women but neglected to warn them of cancer risks tied to the therapy.
Pfizer reported to the U.S. Securities and Exchange Commission on Thursday that it spent $172 million...
Already a subscriber? Click here to login